← All trials
NCT03350906
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2018
- Primary completion
- Dec 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 144
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicReponsible party - principal investigator
- Mayo ClinicOverall official - principal investigator
- National Institute on Aging (NIA)Collaborator
- National Center for Research Resources (NCRR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.